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Abstract: Uric acid used as a marker of cardiovascular risk, which is associated with 
oxidative stress and inflammation. P-wave dispersion (PWD) is an 
electrocardiographic measure, which shows heterogeneity of atrial depolarization. It 
has demonstrated that there is an association of increased PWD with atrial fibrillation. 
This article's goal was to investigate the relationship between PWD and uric acid in 
subjects with heart failure (HF). Methods This descriptive, cross-sectional study 
included a total of 315 stable HF outpatients. The subjects were classified into two 
groups by their PWD: the normal PWD group consisted of subjects with a PWD lower 
than 40 ms (n = 201), and the increased PWD group consisted of subjects with a PWD 
higher than or equal to 40 ms (increased PWD) (n = 114). Results Significantly higher 
uric acid levels determined in the increased PWD group, in comparison with the normal 
PWD group (7.4 ± 1.6 mg/dL, vs. 6.5 ± 1.6 mg/dL p < 0.001). Univariate analyses 
revealed an association between uric acid, blood urea nitrogen, systolic pulmonary 
artery pressure, left atrial diameter, and increased PWD. In multivariate logistic 
regression analysis, there was an association of uric acid level (OR: 1.293; 95% CI: 
1.106-1.511, p: 0.001), systolic pulmonary artery pressure (OR: 1.027; 95% CI: 1.011-
1.044, p: 0.001), and left atrial diameter (OR: 1.754; 95% CI: 1.028-2.992, p: 0.039) 
with PWD. The receiver operating characteristics (ROC) curve analysis demonstrated 
that the optimal cut-off level of uric acid for predicting increased PWD was ≥ 7.1 mg/dL 
with a specificity of 77 percent and a sensitivity of 81 percent. Conclusion Our study 
results suggest that serum uric acid levels independently correlated with PWD in 
subjects with HF. 
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INTRODUCTION 
 Heart failure (HF) represents a complex clinical syndrome, which is related to 
high mortality and morbidity rates (Bui et al, 2011). P-wave dispersion (PWD) 
described as the difference between the longest and shortest P-wave durations on 
12-lead electrocardiography (ECG). Furthermore, PWD is a non-invasive marker of 
heterogeneity of atrial depolarization (Aizawa et al, 2017). Several studies have 
shown that increased PWD can predict atrial fibrillation (AF) (Pérez-Riera et al, 2016). 
AF  and HF commonly coexist. When they exist in conjunction, each condition has a 
more severe course with an increased risk of mortality (Carlisleet al, 2019). Previous 
studies have demonstrated that oxidative stress and inflammation can play a 
significant part in the development of AF in patients with HF (Oikonomou et al, 2019). 
 Uric acid, which represents the final product of purine metabolism, is a 
surrogate marker of inflammation and oxidative stress (Bergamini et al, 2009). The 
xanthine oxidase enzyme mediates its production. A correlation of increased levels 
of uric acid with oxidative stress, endothelial dysfunction, and cardiovascular risk has 
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revealed (Borghi et al, 2018; Shao et al, 2019; Zhao et al, 2012). Nevertheless, a 
relationship of increased uric acid levels with the development of AF has shown in a 
few studies. Best of our knowledge, the relationship between uric acid levels and 
PWD, which is a predictor of AF, has not been studied in subjects with HF in the 
literature. This article's goal was to examine the relationship between PWD and uric 
acid levels in HF subjects. 
  
MATERIALS AND METHOD 
Patients and Methods 
 This descriptive, cross-sectional research involved a total of 315 (142 females 
and 173 males) outpatients with the New York Heart Association (NYHA) functional 
class II, III, and NYHA ambulatory functional Class IV HF. Left ventricular systolic 
dysfunction (a left ventricular ejection fraction of < 50 percent) determined in all of 
the subjects. 12-lead ECG and blood samples obtained on the same day. Patients 
with thyroid dysfunction, gout, infectious diseases, atrial fibrillation, connective tissue 
diseases, neoplastic processes, neurologic disorders, end-stage renal disease, and 
patients taking drugs, which could influence uric acid metabolism (except for 
diuretics), were not included in the research. 
 Written informed consent received from every subject. The Ethics Committee 
of Cumhuriyet University (Sivas, Turkey) approved the study protocol. The research 
carried following the principles of the Declaration of Helsinki. 
ECG examination 
 Twelve-lead ECG acquired following a 10-min rest with a 20 mm/Mv amplitude 
and 50 mm/sec rate with the standard lead positions. The ECG readings were 
evaluated by two cardiologists, blinded to the patient data. P-wave duration 
measurement performed in all leads from the start of the P-wave, which defined as 
the point at the initial deflection of the P-wave crossed the isoelectric line, to the 
ending of the P-wave, which defined as the point at the final deflection of P-wave 
crossed an isoelectric line. Increased PWD defined as a PWD of ≥ 40 
ms(Dilaveris,1998). Increased PWD is associated with AF. Patients in the current 
research classified into two groups based on their PWD: the normal PWD group with 
a PWD < 40 ms (n = 201) and the increased PWD group with a PWD ≥ 40 ms (n = 
114). 
Transthoracic echocardiography examination 
 All patients underwent transthoracic echocardiography (TTE). TTE 
examinations performed using a 2.5 MHz transducer and a Vivid 7 Dimension® (GE 
Vingmed Ultrasound AS, N-3190 Horten, Norway) echocardiography device. The 
measurements carried out in a left-side decubitus position following a rest time of min 
through the standard parasternal long axis, short axis, and apical four- and five-
chamber view windows. The measurements of the interventricular septum thickness, 
left ventricular posterior wall thickness, left ventricle (LV) end-systolic diameter, and 
LV end-diastolic diameter was made just below the mitral valve in the parasternal 
long-axis view using M-mode examination. In the parasternal long-axis view, M-mode 
examination used to measure the left atrium size. The left ventricular ejection fraction 
computed using the biplane Simpson's method from apical four-chamber and two-
chamber views following the recommendation of the American Society of 
Echocardiography (Lang RM et al., 2005). The calculation of the systolic pulmonary 
artery pressure (SPAP) was performed through the peak velocity of tricuspid 
regurgitation and estimated right atrial pressure (Lancelotti et al, 2010). 
significant statistically 
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RESULTS AND DISCUSSION 
 














Age (yr) 65 ± 12 65±13 66 ±12 0,486 
Female                                            142 (%45) 97(%48) 45(%40) 0,132 
Hypertension                                  190(%60) 122(%61) 68(%60) 0,855 
Diabetes mellitus                            128(%41) 87(%43) 41(%36) 0,204 
CAD(%)                             224(%71) 140(%70) 84(%74) 0,440 
BMI (kg/m2) 27±4,0 27±3,7 27±4,4 0,282 
ACE/ARB(%) 271(%86) 173(%86) 98(%86) 1,000 
Beta blocker(%) 284(%90) 181(%90) 103(%90) 1,000 
Thiazides(%) 124(%39) 83(%41) 41(%36) 0,352 
Loop diuretics(%) 205(%65) 131(%65) 74(%65) 1,000 
Aldosterone 
anagonists(%) 
210(%67) 131(%65) 79 (%69) 0,456 
Echocardiographic findings 
LVEF (%)                                            33±6 33±6 33±7 0,753 
LA(cm)                                          4,5 ±0,5 4,4±0,5 4,6±0,5 <0,001 
LVEDD(cm) 5,6 ±0,5 5,5 ±0,6 5,6 ±0,6 0,571 
SPAP (mmhg)                                38±17 34±16 43±16 <0,001 
Laboratory findings 
Hemoglobin (g/dL)                        12,5±2,0 12,5±2,0 12,5±2,0 0,649 
BUN(mg/dL)                                                         23 ± 10 21 ± 10 25 ± 10 0,004 
Creatinine (mg/dL)                             1,0±0,3 1,0±0,3 1,0±0,3 0,092 
Sodium (mmol/L) 136±4 136±4 136±4 0,765 
Potassium(mmol/l) 4,3±0,5 4,3±0,5 4,2±0,5 0,133 
WBC   cells/μl                       7859±2414 7720±2385 8103±2457 0,177 
Platelet (103x cells/μl)                                                                                                                                                                                                                       255±120 255±124 255±114 0,998 
Uric acid (mg/dl) 6,8±1,6 6,5±1,6 7,4±1,6 <0,001 
Abbreviations: PWD, P wave dispersion; DM, diabetes mellitus; CAD, coronary artery 
disease; BMI, body mass index; ACE, angiotensin-converting enzyme; ARB, 
angiotensin receptor blocker; LVEF, left ventricle ejection fraction; LA, left atrial 
diameter; SPAP, systolic pulmonary artery pressure; LVEDD, left ventricle end-
diastolic diameter, BUN, blood urea nitrogen; WBC, white blood cell. 
 
 Three hundred fifteen subjects in total (142 females and 173 males) with an 
average age of 65 ± 12 years enrolled in the present research. The mean body mass 
index (BMI) of the patients was 27 ± 4.0 kg/m2. The BMI values were similar among 
the males and females in this study. Comorbidities of the study population included 
hypertension (60%, n = 190), diabetes mellitus (DM) (41%, n = 128), and coronary 
artery disease (CAD) (71%, n=224). The mean ejection fraction (EF) was 33 ± 6%. 
Significantly higher uric acid levels determined in the increased PWD group in 
comparison with the normal PWD group (7.4 ± 1.6 mg/dL, vs. 6.5 ± 1.6 mg/dL p < 
0.001). The left atrial diameter (LA) and systolic pulmonary artery pressure (SPAP) 
was also significantly higher (4.6 ± 0.5 vs. 4.4 ± 0.5, p<0.001 and 43 ± 16 vs. 34 ± 
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16, p < 0.001, respectively) in the increased PWD group, in comparison with the 
normal PWD group. Baseline characteristics, echocardiographic parameters, and 
laboratory data presented in Table 1. 
           
Table 2. Spearman Correlation Coefficients for PWD  





LA 0,311 <0,001 
LVEDD 0,136 0,016 
SPAP 0,266 <0,001 
BUN 0,295 <0,001 
Creatinin 0,228 <0,001 
Uric acid 0,353 <0,001 
Abbreviations:PWD, P wave dispersion; SPAP,systolic pulmonary artery pressure; LA, 
left atrial diameter; LVEDD, left ventricule enddiastolic diameter BUN, blood ure 
nitrogen 
 
Table 3. Univariate and Multivariate Analyses for Predicting Increased PWD 
 
 Univariate Multivariate 
Variable p OR (95% Cl) P OR (95% Cl) 
Statistically significant variables 
Uric Acid <0,001 1,374 1,185-1,593  0,001 1,293 1,106-1,511 
SPAP <0,001 1,035 1,020-1,051  0,001 1,027 1,011-1,044 
LA <0,001 2,859 1,747-4,679 0,039 1,754 1,028-2,992 
BUN 0,004 1,035 1,011-1,060    
Variables correlating with increased PWD 
Creatinin 0,086 1,812 0,919-3,573    
LVEDD 0,569 1,113 0,760-1,649    
 
All the variables from Table 1 were examined and only those significant at P < 0.05 
level and correlated with PWD are shown in univarite analysis. Multivariate logistic 
regression analysis  including all the variables inunivariate analysis with forward wald  
method.   CI: Confidence interval; OR: odds ratio, PWD, P wave dispersion; SPAP, 
systolic pulmonary artery pressure;  LA,left atrial diameter ; BUN, blood urea nitrogen; 
LVEDD, left ventriculeenddiastolic diameter 
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Figure 1. ROC Curve of Uric Acid to Predict Increased PWD 
 
      As presented in Table 2, uric acid, blood urea nitrogen (BUN), creatinine, left 
atrial diameter, SPAP, and left ventricular end-diastolic diameter positively correlated 
with PWD. Table 3 presents the findings of the univariate and multivariate logistic 
regression analyses for increased PWD. Uric acid, SPAP, left atrial diameter, and 
BUN was associated with increased PWD in univariate analyses. In the multivariate 
logistic regression analysis, uric acid (OR:   1.293;   95%   CI:   1.106-1.511, p: 0.001), 
SPAP (OR: 1.027; 95% CI: 1.011-1.044, p: 0.001), and left atrial diameter (OR: 
1.754; 95% CI: 1.028-2.992, p: 0.039) remained correlated with increased PWD after 
adjusting for the variables that significantly correlated with PWD in the univariate 
analyses. 
 The ROC curve analysis indicated that the optimal cut-off level of uric acid for 
predicting increased PWD was ≥7.1 mg/dl with a specificity of 77% and sensitivity of 
81% (AUC = 0.83, 95% CI = 0.745-0.915, p < 0.001, Figure 1). 
 As far as we know, the current research represents the first study in the 
literature, which shows an independent correlation between PWD and serum uric 
acid levels in subjects with HF. 
 Similar pathophysiological pathways are involved in HF and AF, and the 
concomitance of these two conditions is associated with mortality (Kotecha et al, 
2015). Oxidative stress and inflammation play a significant part in the development 
of AF in subjects with HF (Zacharia et al, 2019). Uric acid, which is the final product 
of purine metabolism, represents an important marker of inflammation and oxidative 
stress. Several studies have suggested a relationship between high uric acid levels 
and the development of AF (Tamariz et al, 2011; Nyrnes et al, 2014). 
 P-wave dispersion, which described as the difference between the longest and 
shortest P-wave duration on 12-lead ECG, represents a non-invasive marker of 
heterogeneity of atrial depolarization. The increased dispersion of atrial refractoriness 
has shown to induce reentry, leading to AF(Pérez-Riera et al, 2016). A PWD of 40 
ms or higher defined as increased PWD. Dilaveris et al. reported that a PWD value 
of 40 ms predicted AF with a sensitivity of 83%, a specificity of 85%, and a positive 
predictive value of 89%(Dilaveris et al,1998). 
AUC=0.83, 95% CI=0.745-0.915, p<0.001 
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 Increased PWD has associated with certain cardiovascular disorders including 
cardiomyopathies, rheumatic mitral valve stenosis, stroke and hypertension all of 
which correlated with a high risk of AF (Dogan et al, 2012; Kocaoglu et al, 2012; 
Russo et al, 2017; Tsioufis et al, 2019). The current study may indicate that the 
association between uric acid and the development of AF can be due to increased 
PWD. 
 Several studies indicated a correlation between uric acid and PWD under 
certain clinical conditions. Su et al. investigated the association between PWD and 
the maximum P-wave duration and rapid deterioration in kidney functions and found 
an independent association between high uric acid levels and increased PWD (β = 
0.281, p = 0.002) (Su et al, 2012). Çakar et al. stated that serum uric acid levels were 
associated with minimum, maximum, and mean P-wave durations in military jet pilots 
and transport aircraft aircrew (r = 0.355, p = 0.002; r = 0.318, p = 0.006; and r = 0.422, 
p < 0.001, respectively) (Çakar et al, 2016). 
 The association between uric acid and PWD may be due to the relationship 
between uric acid and the selective increase in atrial oxidative stress. Uric acid is a 
marker of upregulated xanthine oxidase activity, which leads to the production of 
reactive oxygen species, which induce atrial tissue injury (Bergamini et al,2009). 
Furthermore, uric acid production due to microvascular tissue hypoxia may affect the 
atrial tissue via systemic oxidative stress. Increased xanthine oxidase activity may 
lead to cardiac dysfunction and the progression of HF by inducing oxidative stress 
and uric acid production (Borghi et al, 2019; Huang et al, 2019). Several studies have 
shown that lowering uric acid levels without altering xanthine oxidase activity does 
not provide clinical benefit (George et al,2006; Ogino et al, 2010). Therefore, xanthine 
oxidase activity appears to play a significant part in oxidative stress. Depression of 
cardiac functions and increased oxidative stress may be responsible for atrial fibrosis, 
which may be associated with increased PWD. Moreover, increased uric acid levels 
may increase PWD by inducing endothelial dysfunction and activating the renin-
angiotensin-aldosterone system (Johnson et al, 2005). 
 In the present study, SPAP found to be significantly associated with increased 
PWD. Similarly, Guntekin et al. detected a positive association between SPAP and 
PWD in patients with mitral valve stenosis (r = 0.295, P = 0.047) (Guntekin et al, 
2008). However, in the study by Turhan et al., the decrease in SPAP after mitral 
balloon valvuloplasty was not found to be associated with a parallel decrease in PWD 
(Turhan et al, 2002). Based on these findings, we suggest that the relation between 
SPAP and PWD takes place, as diastolic dysfunction in HF may lead to an increase 
in pulmonary artery pressure in addition to atrial dilatation and fibrosis. The other 
possible explanation is that enhanced sympathetic activity in patients with HF may 
increase both PWD and SPAP to a similar extent (Akutsu et al, 2013; Tukek et al, 
2000). 
 In the present research, the left atrial diameter found to be significantly 
associated with increased PWD. Some studies have also found similar associations, 
while some authors have not shown such an association (Ozyigit et al, 2016; Sarvari 
et al, 2016; Koide et al, 2002; Tukek et al, 2001). P-wave dispersion may be affected 
by the delay in site-dependent intra-atrial conduction before the onset of left atrial 
dilatation (Hatam et al, 2014; Gazi et al, 2015). However, increased sympathetic 
activity may affect the propagation of the sinus impulse in subjects with HF. It has 
also reported that PWD may be affected by increased left atrial pressure, diastolic 
changes, and intra atrial oxidative stress (Gudul et al, 2017).    
 In the current study, BUN and creatinine levels positively correlated with PWD. 
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However, neither BUN nor creatinine was an independent predictor of increased 
PWD in multivariate regression analysis. Another study showed an independent 
association between PWD and deterioration in kidney functions (Su et al, 2012). The 
association between PWD and kidney functions may be due to subclinical 
inflammation, endothelial dysfunction, systemic neurohormonal activation, and 
oxidative stress in patients with kidney disease. 
 Although the clinical implementation of our findings is a little bit difficult and 
dubious, the increased levels of uric acid, as an inflammatory biomarker in heart 
failure, might corrupt the atrial conduction. Our data analysis showed that increased 
levels of uric acid could be a trigger for atrial arrhythmias. Furthermore, large-scale 
studies evaluating the impact of drugs interacting with uric acid metabolism on 
arrhythmias can enlighten this association. 
 Nonetheless, there are a few limitations of the present research. Firstly, this 
study has a small sample size. Secondly, we used the manual measurement of P-
waves by a magnifying lens rather than a computer-assisted calculation. In previous 
studies, digital and signal-averaging ECG systems utilized to evaluate PWD more 
accurately (Tukek et al, 2000; Dilaveris et al, 1999). Thirdly, the current research 
represents a cross-sectional study and further longitudinal studies required for 
confirming the relationship between PWD and uric acid. Another limitation was the 
lack of regular ambulatory ECG monitorization. That is why paroxysmal AF attacks 
could not be recorded. Finally, it is possible that the left atrial maximal diameter, 
measured in the present research, does not represent the left atrial size and volume 
in subjects with HF accurately. 
 
CONCLUSION 
In conclusion, our study results suggest an independent association between 
serum uric acid levels and PWD in subjects with HF. The relationship between 
increased uric acid levels and the development of AF in subjects with HF can originate 
from increased PWD. Furthermore, prospective research with larger sample sizes 
required for confirming this association and demonstrating underlying 
pathophysiological mechanisms. Such studies would also provide information to 
prevent AF in patients with HF. 
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